Comment by: Hugo Schmidt, Portfolio Manager – Healthcare Services and Tools The healthcare sector is one of the world’s most regulated, and the US election naturally has significant impact on future policy decisions. We identify a number of key points from the new administration and Congress that we believe will influence the sector: The Trump […]
News
October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes
Monthly comment – October 2024 During October, the focus was initially on the earnings season where financials performed well. However, the high degree of uncertainty surrounding the election in the US increasingly led to heightened market volatility, where both sectors and individual stocks were affected by the polls. There were significant differences in currencies as […]
Monthly summary – September 2024
As in the previous month, September began with a spike in volatility. Mixed economic data, interest rate uncertainties and geopolitical tensions, all added to a weak start. With the benefit of hindsight, after nine out of the past ten months ended in the green, some profit-taking was perhaps to be expected, particularly bearing in mind […]
Rhenman & Partners strengthens its Investor Relations team further
Rhenman & Partners hires Mattias Hagen as Investor Relations Director. Mattias joins Rhenman & Partners Investor Relations team based in Stockholm consisting of Erica von Bahr and Tom Josephson. In his role, Mattias will work both with Swedish and international investors. Most recently Mattias has worked with institutional investors at Carnegie Fonder. Prior to that […]
Monthly summary – August 2024
SUMMARY August started with a spike in volatility. Despite the initial stress, stock markets increased during the month, with the world index up 2.5 percent, measured in US dollars. Several central banks have now signalled their intention to cut interest rates in the coming months. The US election campaign is in full swing with continued […]
Rhenman & Partners strengthens investment team – hires additional biopharma PM
Rhenman & Partners hires Camilla Oxhamre Cruse as Portfolio Manager – biotech and pharma. She will have a particular focus on companies within pharmaceutical development. Camilla joins Rhenman & Partners’ investment team of four people, all based in their Stockholm office. Camilla has a master’s degree in biochemistry from Lund University (Lund) and obtained a […]
Monthly update – July 2024
Stock markets increased slightly in July with the world index up 1.7 percent, measured in US dollars. A significant rotation from former stock market winners, mainly in technology, to value stocks and smaller companies was an important phenomenon during the month. The technology companies’ reports indicated slightly lower growth momentum, while smaller companies on the […]
Monthly summary – June 2024
Events during the month of June centered on the continuing geopolitical unrest around the world. The war in Ukraine intensified, negotiations to reach a ceasefire in the Gaza Strip failed, and Putin and Kim Jong Un deepened their cooperation. Financially, June saw overall strong equity markets, especially for the technology sector, but consumer-driven companies in […]
Rhenman & Partners celebrates 15 years
On 21 May Rhenman & Partners took the opportunity to celebrate 15 successful years by inviting guests to a seminar in Stockholm. The article below is a summary of the day and captures the key messages from each presentation. Click here to read or download the article as a PDF. Rhenman & Partners celebrates […]